@article{e093361ec8fa411aab81bb114a91fe32,
title = "Examination on lifting motion with different start-on posture, and study on the proper opration using minimum jerk model",
abstract = "The aim of this research is to establish the quantitative evaluation method for lifting task and to clarify the safety posture and optimal motion. This paper firstly examines the operation from differenet three start-on postures with four items: the maximum compressive force and share force on L5/S1 joint, the energy efficiency index, and the degree of contribution of each joint. As a result it has been shown that the load not only to lumbar vertebra but to knee joint should be emphasized and the pose-C is an appropriate start on posture in which the knee is flexed almost at right-angled and the upper body is raised. Moreover from the simulation using minimum jerk model we found a proper operation, but the actual operation has earlier timing to extend the lower body than presumed. So not only the criteria on the whole operation or the relative criteria but also the absolute criteria paying attention to a portion like knee joint moment seems necessary to study the optimal lifting motion.",
keywords = "Human motion analysis, Minimum jerk model, Optimal operation, Start-on posture, Weight lifting task",
author = "Takafumi Matsumaru and Satoshi Fukuyama and Kazuyoshi Shima and Tomotaka Ito",
note = "Funding Information: The work was supported by the Multiple Sclerosis Research Australia Postdoctoral Fellowship [11-054] and NHMRC Early Career Award (Clinical) to TK [1071124], NHMRC Career Development Award (Clinical) to HB [628856], NHMRC Project Grant [1032484], NHMRC Centre for Research Excellence [1001216] and the MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering, Sanofi-Aventis and BioCSL. The study was conducted separately and apart from the guidance of the sponsors. TK had full access to all the data and takes responsibility for integrity of the data and accuracy of the data analysis. Funding Information: Eva Havrdova received speaker honoraria and consultant fees from Biogen Idec, Merck Serono, Novartis, Genzyme and Teva, as well as support for research activities from Biogen Idec and Merck Serono. Francois Grand{\textquoteright}Maison received honoraria from Biogen Idec, Genzyme, Novartis and Roche. Fraser Moore has participated in clinical trials sponsored by EMD Serono and Novartis. Freek Verheul did not declare any competing interests. Gerardo Iuliano had travel/accommodations/meeting expenses funded by Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, and Teva Guillermo Izquierdo received speaking honoraria from Biogen Idec, Novartis, Sanofi, Serono and Teva. Helmut Butzkueven has served on scientific advisory boards for Biogen Idec, Novartis and Sanofi-Aventis and has received conference travel support from Novartis, Biogen Idec and Sanofi Aventis. He serves on steering committees for trials conducted by Biogen Idec and Novartis, and has received research support from Merck Serono, Novartis and Biogen Idec. Jeannette Lechner-Scott has accepted travel compensation from Novartis, Biogen and Merck Serono. Her institution receives the honoraria for talks and advisory board commitment and also clinic support from Bayer Health Care, Biogen Idec, CSL, Genzyme Sanofi, Merck Serono and Novartis. Jose Antonio Cabrera-Gomez did not declare any competing interests. Marc Girard received consulting fees from Teva Canada Innovation, Biogen Idec, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD Serono and a research grant from Canadian Institutes of Health Research. Maria Laura Saladino did not declare any competing interests. Maria Pia Amato received honoraria as consultant on scientific advisory boards by Biogen Idec, Bayer Schering, Merck-Serono, Teva and Sanofi-Aventis; has received research grants by Biogen Idec, Bayer Schering, Merck-Serono, Teva and Novartis. Funding Information: Mark Paine received travel grants from Novartis, Bayer Schering, Merck-Serono, Biogen Idec and honoraria from Novartis, BioCSL, Bayer Schering, and Biogen Idec. Funding Information: Maria Trojano received speaking honoraria from Biogen Idec, Bayer Schering, Sanofi Aventis, Merck-Serono, Teva and Novartis; has received research grants from Biogen Idec, Merck-Serono, and Novartis.",
year = "2006",
month = aug,
doi = "10.1299/kikaic.72.2554",
language = "English",
volume = "72",
pages = "2554--2561",
journal = "Nihon Kikai Gakkai Ronbunshu, C Hen/Transactions of the Japan Society of Mechanical Engineers, Part C",
issn = "0387-5024",
publisher = "Japan Society of Mechanical Engineers",
number = "8",
}